With only six months left until July 1, 2026, the implementation of Article 75 of the National Medical Products Administration's "Special Regulations on the Registration of Traditional Chinese Medicine" is entering its final window period. This regulation, referred to in the industry as the "death clause" for proprietary Chinese medicines, clearly states that after three years of implementation starting from July 1, 2023, the contraindications in the instructions will be prohibitedWallstreetcn·Jan 27, 2026 at 10:41 AM512290-1.79%159929-0.99%
YILING PHARMACEUTICAL: It is expected that the net profit in 2025 will be between 1.2 billion and 1.7 billion yuan, compared to a loss of 725 million yuan in the same period last yearWallstreetcn·Jan 22, 2026 at 09:06 AM002603-0.65%
The morning session of the 2025 National Conference opens: CR Sanjiu and YILING PHARMACEUTICAL enter the arena, negotiations on traditional Chinese medicine varieties beginZhitong·Nov 2, 2025 at 12:59 AM002603-0.65%000999+1.64%
Zhejiang Merchants Securities: Upgrades YILING PHARMACEUTICAL to "Buy" rating, with future performance expected to continue improvingZhitong·Oct 30, 2025 at 06:44 AM002603-0.65%
YILING PHARMACEUTICAL: Wholly-owned subsidiary Anastrozole raw material drug has received the approval notice for listing applicationZhitong·Oct 29, 2025 at 08:19 AM002603-0.65%
YILING PHARMACEUTICAL: The safflower base has undergone extended inspection according to the "Quality Management Standards for the Production of Traditional Chinese Medicinal Materials."Zhitong·Oct 13, 2025 at 12:52 AM002603-0.65%
YILING PHARMACEUTICAL: The new drug registration application for the innovative traditional Chinese medicine Xiaoer Lianhua Qinggan Granules has been acceptedZhitong·Aug 19, 2025 at 09:07 AM002603-0.65%
Can Lianhua Qingwen treat Chikungunya fever? YILING PHARMACEUTICAL respondsZhitong·Aug 6, 2025 at 08:30 AM002603-0.65%
YILING PHARMACEUTICAL: Banxia Baizhu Tianma granules accepted for registration by the National Medical Products AdministrationZhitong·Jul 10, 2025 at 08:54 AM002603-0.65%
The monoclonal antibody concept was active at the beginning of the trading session, with Science Sun Pharm and HAINAN HAIYAO both rising over 9%, while YILING PHARMACEUTICAL, Zhongyuan Union, and FUDANZHANGJIANG also saw gainsZhitong·Jul 8, 2025 at 01:36 AM688505-2.97%01349-2.09%
YILING PHARMACEUTICAL: Chemical drug innovation "G201-Na capsule" clinical trial application approvedZhitong·Jul 7, 2025 at 11:05 AM002603-0.65%
YILING PHARMACEUTICAL: Chemical drug innovation "G201-Na capsule" clinical trial application has been acceptedZhitong·Apr 29, 2025 at 08:34 AM002603-0.65%
YILING PHARMACEUTICAL: Letrozole raw material drug has received approval for listing applicationZhitong·Apr 27, 2025 at 08:21 AM002603-0.65%
YILING PHARMACEUTICAL: The new drug registration application for "Qi Gui Luo Bi Tong Pian" has been acceptedZhitong·Apr 7, 2025 at 10:29 AM002603-0.65%
YILING PHARMACEUTICAL has established a new subsidiary in Chengdu, including a traditional Chinese medicine acquisition businessZhitong·Mar 4, 2025 at 07:51 AM002603-0.65%
